Skip to content
easybpt
Browse topics

Pharmacology

Tricyclic, MAOI and atypical antidepressants

The receptor profile of tricyclics and how it predicts their adverse effects and lethal toxicity, irreversible and reversible MAO inhibition and the tyramine reaction, and the mechanisms of mirtazapine, agomelatine, vortioxetine, reboxetine, bupropion and esketamine.

Tier 2Medical sciences concept

Written with AI assistance and fact-checked against the sources below. For exam study, not clinical decisions. How notes are made

3 questions8 flashcards

At a glance

  • Tricyclics (TCAs) inhibit serotonin and noradrenaline reuptake but also block muscarinic, histamine and alpha-1 receptors and cardiac sodium channels. That "dirty" profile explains their adverse effects and their lethality in overdose.
  • MAOIs stop breakdown of monoamines. Irreversible non-selective MAOIs (phenelzine, tranylcypromine) carry the tyramine reaction and dangerous interactions. Moclobemide is a reversible MAO-A inhibitor with far fewer problems.
  • Atypical antidepressants each have a distinct mechanism: mirtazapine (alpha-2 antagonist), agomelatine (melatonergic), vortioxetine (multimodal serotonergic), reboxetine (NRI), bupropion (noradrenaline and dopamine reuptake inhibitor) and esketamine (NMDA antagonist).

Loading the rest of the note…

Finished reading?

Test yourself on it:3 questions8 flashcards

Sources

Last updated
14 November 2026
What changed
  • 14 November 2026 Turnstile bot check on sign-in and signed-out feedback

Send feedback

Type of feedback

The page you're on and your device type are attached automatically.